🚀 VC round data is live in beta, check it out!
Boundless Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Boundless Bio and similar public comparables like Advicenne, Xintela, Diamyd Medical, NeuroSense Therapeutics and more.
Boundless Bio Overview
About Boundless Bio
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
Founded
2018
HQ
Employees
64
Website
Sectors
Financials (LTM)
Market Cap
$26M
Boundless Bio Financials
Boundless Bio reported last 12-month revenue of — and negative EBITDA of ($58M).
In the same LTM period, Boundless Bio generated ($58M) in EBITDA losses and had net loss of ($58M).
Revenue (LTM)
Boundless Bio P&L
In the most recent fiscal year, Boundless Bio reported revenue of — and EBITDA of ($56M).
Boundless Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($58M) | XXX | ($56M) | XXX | XXX | XXX |
| Net Profit | ($58M) | XXX | ($58M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Boundless Bio Stock Performance
Boundless Bio has current market cap of $26M.
Market Cap Evolution
Boundless Bio's stock price is $1.14.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $26M | -1.7% | XXX | XXX | XXX | $-2.60 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBoundless Bio Valuation Multiples
Boundless Bio trades at 0.6x EV/EBITDA.
Boundless Bio Financial Valuation Multiples
As of April 11, 2026, Boundless Bio has market cap of $26M.
Equity research analysts estimate Boundless Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Boundless Bio has a P/E ratio of (0.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $26M | XXX | $26M | XXX | XXX | XXX |
| EV (current) | ($33M) | XXX | ($33M) | XXX | XXX | XXX |
| EV/EBITDA | 0.6x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBIT | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| P/E | (0.4x) | XXX | (0.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Boundless Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Boundless Bio Margins & Growth Rates
Boundless Bio's revenue in the last fiscal year grew by —.
Boundless Bio's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.
Boundless Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 12% | XXX | 14% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Boundless Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Advicenne | XXX | XXX | XXX | XXX | XXX | XXX |
| Xintela | XXX | XXX | XXX | XXX | XXX | XXX |
| Diamyd Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| NeuroSense Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tevogen Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Boundless Bio M&A Activity
Boundless Bio acquired XXX companies to date.
Last acquisition by Boundless Bio was on XXXXXXXX, XXXXX. Boundless Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Boundless Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBoundless Bio Investment Activity
Boundless Bio invested in XXX companies to date.
Boundless Bio made its latest investment on XXXXXXXX, XXXXX. Boundless Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Boundless Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Boundless Bio
| When was Boundless Bio founded? | Boundless Bio was founded in 2018. |
| Where is Boundless Bio headquartered? | Boundless Bio is headquartered in United States. |
| How many employees does Boundless Bio have? | As of today, Boundless Bio has over 64 employees. |
| Who is the CEO of Boundless Bio? | Boundless Bio's CEO is Zachary D. Hornby. |
| Is Boundless Bio publicly listed? | Yes, Boundless Bio is a public company listed on Nasdaq. |
| What is the stock symbol of Boundless Bio? | Boundless Bio trades under BOLD ticker. |
| When did Boundless Bio go public? | Boundless Bio went public in 2024. |
| Who are competitors of Boundless Bio? | Boundless Bio main competitors are Advicenne, Xintela, Diamyd Medical, NeuroSense Therapeutics. |
| What is the current market cap of Boundless Bio? | Boundless Bio's current market cap is $26M. |
| Is Boundless Bio profitable? | No, Boundless Bio is not profitable. |
| What is the current EBITDA of Boundless Bio? | Boundless Bio has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Boundless Bio? | Current EBITDA multiple of Boundless Bio is 0.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.